{"id":"vildagliptin-acarbose","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Gastrointestinal symptoms (e.g., diarrhea, flatulence)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"Vildagliptin inhibits DPP-4, which increases levels of GLP-1 and GIP, leading to enhanced insulin secretion. Acarbose inhibits alpha-glucosidase enzymes in the small intestine, slowing down the breakdown of carbohydrates and reducing postprandial glucose spikes.","oneSentence":"Vildagliptin and acarbose work together to improve blood glucose control by enhancing insulin secretion and reducing carbohydrate absorption.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:37.244Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT03492580","phase":"","title":"A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-02-22","conditions":"Diabetes Mellitus, Type 2, Cardiovascular Diseases","enrollment":714582},{"nctId":"NCT06449235","phase":"PHASE4","title":"Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh","status":"NOT_YET_RECRUITING","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2024-09","conditions":"Type2diabetes","enrollment":938},{"nctId":"NCT02999841","phase":"PHASE4","title":"Effect of Acarbose and Vildagliptin on Visceral Fat Distribution in Newly Diagnosed Type 2 Diabetes Patients","status":"UNKNOWN","sponsor":"Peking University","startDate":"2016-03","conditions":"Diabetes Mellitus, Type 2, Obesity","enrollment":100},{"nctId":"NCT02476760","phase":"","title":"Incretin-based Drugs and Acute Pancreatitis","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Diabetes Mellitus, Type 2","enrollment":1417914},{"nctId":"NCT02456428","phase":"","title":"Incretin-based Drugs and the Risk of Heart Failure","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Type 2 Diabetes Mellitus","enrollment":1499650},{"nctId":"NCT02475499","phase":"","title":"Incretin-based Drugs and Pancreatic Cancer","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Diabetes Mellitus, Type 2","enrollment":886172},{"nctId":"NCT00110240","phase":"PHASE3","title":"Efficacy and Safety of Vildagliptin Compared to Acarbose in Drug Naive Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-04","conditions":"Diabetes Mellitus, Type 2","enrollment":594},{"nctId":"NCT01000688","phase":"PHASE3","title":"Vildagliptin and Endothelium-dependent Vasodilatation","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2010-01","conditions":"Type 2 Diabetes, Endothelial Dysfunction","enrollment":16}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":22,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"vildagliptin + acarbose","genericName":"vildagliptin + acarbose","companyName":"Radboud University Medical Center","companyId":"radboud-university-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vildagliptin is a small molecule that works as a dipeptidyl peptidase-4 (DPP-4) inhibitor, according to ChEMBL. Vildagliptin in combination with acarbose has been studied in clinical trials for conditions such as type 2 diabetes and obesity, including a trial examining its effect on visceral fat distribution in newly diagnosed type 2 diabetes patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}